“3D Cell Culture Market Worth $933.56 Million in 2019”, says Visiongain report

19 December 2019
Pharma

Visiongain’s new report the 3D Cell Culture Market Report  2019-2029: Forecasts by Product (Scaffold-Based, Scaffold-Free, Microfluidics-Based, Magnetic Levitation & 3D Bioprinting), by Application (Cancer, Stem Cell Research, Drug Discovery and Toxicology Testing, Tissue Engineering and Regenerative Medicine, Others), by End User (Pharmaceutical & Biotechnology Companies, Research Institutes, Hospitals, and diagnostic centers, Others) plus analysis of leading companies indicates that the global 3D cell culture market will attain $5.9 billion revenue by 2029.

Global 3D Cell Culture Market is expected to grow on account of rising interest in tissue engineering and drug discovery owing to evident benefits of offering more physiologically appropriate information and more predictive data for in vivo tests. The market is expected to grow at a healthy CAGR of 20.2% over the projected period.

Over the previous few centuries, 2D cell culture technique has traditionally been used not only to examine different in vitro cell types but also to screen and test drugs. This monolayer scheme typically enables the development of cells over a polyester or glass flat surface with a medium that feeds the increasing population of cells. Thanks to 2D cell culture, there have been countless biological breakthroughs. However, this model cannot correctly portray and simulate the wealthy atmosphere and complicated procedures observed in vitro like cell signaling or chemistry. Consequently, information collected for in vivo applications using 2D cell culture techniques could be non-predictive and inaccurate. That's why researchers have been working on 3D biomimetic cell cultures lately, a method that more reflects the real micro-environment in which cells thrive in vivo.

It is expected that the emergence of scaffold-free technology is a promising platform for tissue translation pathway which is anticipated to spur the growth of three-dimensional cell culture methods. In addition, the introduction of three-dimensional bioprinting, which facilitates the manufacturing of scaffold-free tissue units by fusing tissue spheroids, allows the development of functional tissue-engineered buildings with distinct 3D structures. Such developments are expected to drive the development of the 3D cell culture industry.

Growth is motivated by growing R&D investments in 3D cell culture methods. Furthermore, the existence of organizations such as the International Stem Cell Research Society provides financing assistance and fosters scientific growth. This is expected in the near future to increase demand for three-dimensional cell culture techniques.

In 2019, North America 3D Cell Culture Market accounted for more than 30% of overall market share due to growing healthcare expenditure in the U.S & Canada along with a need to deal with rising chronic diseases. Further, the presence of numerous pharma and biotech companies implementing the technology in collaboration with research laboratories drives this regional market at a lucrative CAGR over the forecast period.

Asia Pacific region is expected to experience the highest growth in term of CAGR over the forecast period owing to the development of healthcare infrastructure in this region, combined with increased awareness among the population of upcoming healthcare technologies. The Asia Pacific is home to over 60.0% of the world's population; hence, even low prevalence of chronic diseases converts into a large number of infected individuals, which is the major factor driving growth in this region. Furthermore, unmet needs of patients and untapped areas in this region have been attracting global players and this is expected to boost revenue generation through to 2029.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever